Cowen and Company’s iShares Biotechnology ETF IBB Stock Holding History

Cowen and Company’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-29,600	Closed	-$21K	–	664
2021 Q4	$21K	Buy	+29,600	New	+$4.58M	﹤0.01%	527
2020 Q1	–	Sell	-50,000	Closed	-$129K	–	480
2019 Q4	$129K	Buy	+50,000	New	+$5.58M	0.01%	245

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cowen and Company's IBB Position: Q1 2022 in Review

Cowen and Company sold out of iShares Biotechnology ETF (IBB) in Q1 2022, closing a stake of 4,839 shares — an estimated $739K sold.

Cowen and Company first reported a position in IBB in Q3 2020 and held it in 3 quarters. The position peaked at $1.49M in Q3 2020. 898 funds tracked by Wall St. Rank hold IBB as of Q1 2022.

Cowen and Company reported no remaining iShares Biotechnology ETF position as of Q1 2022 after selling out during the quarter.
Cowen and Company sold 4,839 iShares Biotechnology ETF shares in Q1 2022, an estimated $739K.
Cowen and Company first reported a position in iShares Biotechnology ETF in Q3 2020 and held it in 3 quarters.
Cowen and Company's iShares Biotechnology ETF position peaked at $1.49M in Q3 2020.
898 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2022.

Based on Cowen and Company's 13F filing for Q1 2022, filed 16 May 2022.